Overview

Observation Study of T-Gel (1%) in Treatment of Adolescent Boys With Hypogonadism

Status:
Completed
Trial end date:
2007-03-01
Target enrollment:
Participant gender:
Summary
This study is to observe efficacy and safety after T-Gel 1% treatment in delayed puberty adolescents. Subjects who complete this trial may enter a 3 month extension study (UMD-01-090E).
Phase:
Phase 2
Details
Lead Sponsor:
Solvay Pharmaceuticals
Collaborator:
Unimed Pharmaceuticals
Treatments:
Methyltestosterone
Testosterone
Testosterone 17 beta-cypionate
Testosterone enanthate
Testosterone undecanoate